The thrombospondins

Cold Spring Harbor Perspectives in Biology

Volumn 3, Issue 10, 2011, Pages 1-29

  Adams, Josephine C ^a   Lawler, Jack ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

THROMBOSPONDIN;

AMINO ACID SEQUENCE; ANIMAL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DROSOPHILA; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DROSOPHILA; EVOLUTION, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; THROMBOSPONDINS;

EID: 84863897673     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009712     Document Type: Article

References (308)

1. Adams JC. 2001. Thrombospondins: Multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17: 25-51.
2. Adams JC. 2004. Functions of the conserved thrombospondin carboxy-terminal cassette in cell-extracellular matrix interactions and signaling. Int J Biochem Cell Biol 36: 1102-1114.
3. Adams J, Lawler J. 1993. Extracellular matrix: The thrombospondin family. Curr Biol 3: 188-190.
4. Adams JC, Tucker RP. 2000. The thrombospondin type 1 repeat (TSR) superfamily: Diverse proteins with related roles in neuronal development. Dev Dyn 218: 280-299.
5. Adams JC, Clelland JD, Collett GD, Matsumura F, Yamashiro S, Zhang L. 1999. Cell-matrix adhesions differentially regulate fascin phosphorylation. Mol Biol Cell 10: 4177-4190.
6. Adams JC, Monk R, Taylor AL, Ozbek S, Fascetti N, Baumgartner S, Engel J. 2003. Characterisation of Drosophila thrombospondin defines an early origin of pentameric thrombospondins. J Mol Biol 328: 479-494.
7. Adams JC, Bentley AA, Kvansakul M, Hatherley D, Hohenester E. 2008. Extracellular matrix retention of thrombospondin 1 is controlled by its conserved Cterminal region. J Cell Sci 121: 784-795.
8. AdolphKW. 1999. Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem Biophys Res Commun 258: 792-796.
9. Agah A, Kyriakides TR, Lawler J, Bornstein P. 2002. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161: 831-839.
10. Agah A, Kyriakides TR, Bornstein P. 2005. Proteolysis of cellsurface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 167: 81-88.
11. Albo D, Berger DH, Tuszynski GP. 1998. The effect of thrombospondin-1 and TGF-β 1 on pancreatic cancer cell invasion. J Surg Res 76: 86-90.
12. Alcorn JL, Merritt TM, Farach-Carson MC, Wang HH, Hecht JT. 2009. Ribozyme-mediated reduction of wildtype and mutant cartilage oligomeric matrix protein (COMP) mRNA and protein. RNA 15: 686-695.
13. Alford AI, Terkhorn SP, Reddy AB, Hankenson KD. 2010. Thrombospondin-2 regulates matrix mineralization in MC3T3-E1 pre-osteoblasts. Bone 46: 464-471.
14. Anilkumar N, Annis DS, Mosher DF, Adams JC. 2002. Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci 115: 2357-2366.
15. Anilkumar N, Parsons M, Monk R, Ng T, Adams JC. 2003. Interaction of fascin and protein kinase Cα: A novel intersection in cell adhesion and motility. EMBO J 22: 5390-5402.
16. Annis DS, Gunderson KA, Mosher DF. 2007. Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282: 27067-27075.
17. Arber S, Caroni P. 1995. Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. J Cell Biol 131: 1083-1094.
18. Asch AS, Silbiger S, Heimer E, Nachman RL. 1992. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun 182: 1208-1217.
19. Bale MD, Mosher DF. 1986. Thrombospondin is a substrate for blood coagulation factor XIIIa. Biochemistry 25: 5667-5673.
20. Barros CS, Franco SJ, Müller U. 2010. Extracellular matrix: Functions in the nervous system. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a005108.
21. Bein K, Simons M. 2000. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173.
22. Bentley AA, Adams JC. 2010. The evolution of thrombospondins and their ligand-binding activities. Mol Biol Evol 27: 2187-2197.
23. Blair P, Flaumenhaft R. 2009. Platelet α-granules: Basic biology and clinical correlates. Blood Rev 23: 177-189.
24. Blake SM, Strasser V, Andrade N, Duit S, Hofbauer R, Schneider WJ, Nimpf J. 2008. Thrombospondin-1 binds to ApoER2 and VLDL receptor and functions in postnatal neuronal migration. EMBO J 27: 3069-3080.
25. Blumbach K, Bastiaansen-Jenniskens YM, DeGroot J, Paulsson M, van Osch GJ, Zaucke F. 2009. Combined role of type IX collagen and cartilage oligomeric matrix protein in cartilage matrix assembly: Cartilage oligomeric matrix protein counteracts type IX collagen-induced limitation of cartilage collagen fibril growth in mouse chondrocyte cultures. Arthritis Rheum 60: 3676-3685.
26. Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vermylen J, Lawler J, Hoylaerts MF. 2006. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWFfrom cleavage byADAMTS13. Blood 107: 955-964.
27. Bornstein P, Agah A, Kyriakides TR. 2004. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol 36: 1115-1125.
28. BriggsMD, Chapman KL. 2002. Pseudoachondroplasia and multiple epiphyseal dysplasia: Mutation review, molecular interactions, and genotype to phenotype correlations. Hum Mutat 19: 465-478.
29. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES, et al. 1995. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 10: 330-336.
30. 0UTR T. G single nucleotide polymorphism of thrombospondin-2 gene in sudden death due to plaque erosion. Cardiovasc Pathol 19: e45-e49.
31. Cáceres M, Suwyn C, Maddox M, Thomas JW, Preuss TM. 2007. Increased cortical expression of two synaptogenic thrombospondins in human brain evolution. Cereb Cortex 17: 2312-2321.
32. Calzada MJ, Sipes JM, Krutzsch HC, Yurchenco PD, Annis DS, Mosher DF, Roberts DD. 2003. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by a6b1 integrin. J Biol Chem 278: 40679-40687.
33. Calzada MJ, Zhou L, Sipes JM, Zhang J, Krutzsch HC, Iruela-Arispe ML, Annis DS, Mosher DF, Roberts DD. 2004a. a4b1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res 94: 462-470.
34. Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J, Mosher DF, Roberts DD. 2004b. Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 279: 41734-41743.
35. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J. 2010. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12: 275-283.
36. Canfield AE, Sutton AB, Hoyland JA, Schor AM. 1996. Association of thrombospondin-1with osteogenic differentiation of retinal pericytes in vitro. J Cell Sci 109: 343-353.
37. Carlson CB, Bernstein DA, Annis DS, Misenheimer TM, Hannah BL, Mosher DF, Keck JL. 2005. Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Mol Biol 12: 910-914.
38. Carlson CB, Gunderson KA, Mosher DF. 2008a. Mutations targeting intermodular interfaces or calcium binding destabilize the thrombospondin-2 signature domain. J Biol Chem 283: 27089-27099.
39. Carlson CB, Liu Y, Keck JL, Mosher DF. 2008b. Influences of the N700S thrombospondin-1 polymorphism on protein structure and stability. J Biol Chem 283: 20069-20076.
40. Chanana B, Graf R, Koledachkina T, Pflanz R, Vorbrüggen G. 2007. αPS2 integrin-mediated muscle attachment in Drosophila requires the ECM protein thrombospondin. Mech Dev 124: 463-475.
41. Chen H, Strickland DK, Mosher DF. 1996a. Metabolism of thrombospondin 2. Binding and degradation by 3t3 cells and glycosaminoglycan-variant Chinese hamster ovary cells. J Biol Chem 271: 15993-15999.
42. Chen H, Sottile J, Strickland DK, Mosher DF. 1996b. Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and lowdensity-lipoprotein receptor-related protein: Localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1. Biochem J 318: 959-963.
43. Chen YW, Zhao P, Borup R, Hoffman EP. 2000. Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology. J Cell Biol 151: 1321-1336.
44. Chen FH, Thomas AO, Hecht JT, Goldring MB, Lawler J. 2005. Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J Biol Chem 280: 32655-32661.
45. Chen FH, Herndon ME, Patel N, Hecht JT, Tuan RS, Lawler J. 2007. Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem 282: 24591-24598.
46. Chen TL, Posey KL, Hecht JT, Vertel BM. 2008. COMP mutations: Domain-dependent relationship between abnormal chondrocyte trafficking and clinical PSACH and MED phenotypes. J Cell Biochem 103: 778-787.
47. Cho CH, Kammerer RA, Lee HJ, SteinmetzMO, Ryu YS, Lee SH, Yasunaga K, Kim KT, Kim I, Choi HH, et al. 2004. COMP-Ang1: A designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci 101: 5547-5552.
48. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. 2005. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120: 421-433.
49. Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, Stravalaci M, Tomaselli S, Giavazzi R, Rusnati M, et al. 2010. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: An integrated strategy for the development of newantiangiogenic compounds. J Biol Chem 285: 8733-8742.
50. Corless CL, Mendoza A, Collins T, Lawler J. 1992. Colocalization of thrombospondin and syndecan during murine development. Dev Dyn 193: 346-358.
51. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. 1998. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93: 1159-1170.
52. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. 2004. Roles of thrombospondin-1 and-2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 45: 1117-1124.
53. Daniel C, Schaub K, Amann K, Lawler J, Hugo C. 2007a. Thrombospondin-1 is an endogenous activator of TGF-β in experimental diabetic nephropathy in vivo. Diabetes 56: 2982-2989.
54. Daniel C, Amann K, Hohenstein B, Bornstein P, Hugo C. 2007b. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol 18: 788-798.
55. DawsonDW, Pearce SF, Zhong R, Silverstein RL, FrazierWA, Bouck NP. 1997. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717.
56. DawsonDW, VolpertOV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. 1999. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55: 332-338.
57. de la Fuente H, Lamana A, Mittelbrunn M, Perez-Gala S, Gonzalez S, García-Diez A, Vega M, Sanchez-Madrid F. 2009. Identification of genes responsive to solar simulated UV radiation in human monocyte-derived dendritic cells. PLoS One 4: e6735.
58. DiCesare PE, Mörgelin M, Mann K, Paulsson M. 1994a. Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 223: 927-937.
59. DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M. 1994b. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 354: 237-240.
60. DiCesare PE, Carlson CS, Stollerman ES, Chen FS, Leslie M, Perris R. 1997. Expression of cartilage oligomeric matrix protein by human synovium. FEBS Lett 412: 249-252.
61. DiCesare PE, Chen FS, Moergelin M, Carlson CS, Leslie MP, Perris R, Fang C. 2002. Matrix-matrix interaction of cartilage oligomeric matrix protein and fibronectin. Matrix Biol 21: 461-470.
62. Dickinson SC, Vankemmelbeke MN, Buttle DJ, Rosenberg K, Heinegård D, Hollander AP. 2003. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol 22: 267-278.
63. Dixit VM, Grant GA, Santoro SA, Frazier WA. 1984. Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem 259: 10100-10105.
64. Dunkle ET, Zaucke F, Clegg DO. 2007. Thrombospondin-4 and matrix three-dimensionality in axon outgrowth and adhesion in the developing retina. Exp Eye Res 84: 707-717.
65. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. 2007. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Can Res 13: 6689-6695.
66. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, Mulinyawe SB, Annis DS, Huberman AD, et al. 2009. Gabapentin receptor α2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139: 380-392.
67. Fang C, Carlson CS, Leslie MP, Tulli H, Stolerman E, Perris R, Ni L, Di Cesare PE. 2000. Molecular cloning, sequencing, and tissue and developmental expression of mouse cartilage oligomeric matrix protein (COMP). J Orthop Res 18: 593-603.
68. Fouladkou F, Lu C, Jiang C, Zhou L, She Y, Walls JR, Kawabe H, Brose N, Henkelman RM, Huang A, et al. 2010. The ubiquitin ligase Nedd4-1 is required for heart development and is a suppressor of thrombospondin-1. J Biol Chem 285: 6770-6780.
69. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. 2005. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 111: 2935-2942.
70. Franzen A, Heinegard D, Solursh M. 1987. Evidence for sequential appearance of cartilage matrix proteins in developing mouse limbs and in cultures of mouse mesenchymal cells. Differentiation 36: 199-210.
71. Frieda S, Pearce A, Wu J, Silverstein RL. 1995. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36. J Biol Chem 270: 2981-2986.
72. Frolova EG, Pluskota E, Krukovets I, Burke T, Drumm C, Smith JD, Blech L, Febbraio M, Bornstein P, Plow EF, et al. 2010. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res 107: 1313-1325.
73. Furukawa K, Roberts DD, Endo T, Kobata A. 1989. Structural study of the sugar chains of human platelet thrombospondin. Arch Biochem Biophys 270: 302-312.
74. Galvin NJ, Vance PM, Dixit VM, Fink B, Frazier WA. 1987. Interaction of human thrombospondin with types I-V collagen: Direct binding and electron microscopy. J Cell Biol 104: 1413-1422.
75. Gath U, Hakvoort A, Wegener J, Decker S, Galla HJ. 1997. Porcine choroid plexus cells in culture: Expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components. Eur J Cell Biol 74: 68-78.
76. Giannoni P, Siegrist M, Hunziker EB, Wong M. 2003. The mechanosensitivity of cartilage oligomeric matrix protein (COMP). Biorheology 40: 101-109.
77. Gilsohn E, Volk T. 2010. Slowdown promotes muscle integrity by modulating integrin-mediated adhesion at the myotendinous junction. Development 137: 785-794.
78. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. 1995. Identification of the low density lipoprotein receptorrelated protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 129: 1403-1410.
79. Goicoechea S, Orr AW, Pallero MA, Eggleton P, Murphy-Ullrich JE. 2000. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem 275: 36358-36368.
80. Greenaway J, Gentry PA, Feige JJ, LaMarre J, Petrik JJ. 2005. Thrombospondin and vascular endothelial growth factor are cyclically expressed in an inverse pattern during bovine ovarian follicle development. Biol Reprod 72: 1071-1078.
81. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J. 2007. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210: 807-818.
82. Greenwood JA, Theibert AB, Prestwich GD, Murphy-Ullrich JE. 2000. Restructuring of focal adhesion plaques by PI 3-kinase. Regulation by PtdIns (3,4,5)-p(3) binding to α-actinin. J Cell Biol 150: 627-642.
83. Gruber HE, Bornstein P, Sage EH, Ingram JA, Zinchenko N, Norton HJ, Hanley EN Jr. 2008. Disruption of the thrombospondin-2 gene alters the lamellar morphology but does not permit vascularization of the adult mouse lumbar disc. Arthritis Res Ther 10: R96.
84. Gunasekar SK, Asnani M, Limbad C, Haghpanah JS, Hom W, Barra H, Nanda S, Lu M, Montclare JK. 2009. N-terminal aliphatic residues dictate the structure, stability, assembly, and small molecule binding of the coiled-coil region of cartilage oligomeric matrix protein. Biochemistry 48: 8559-8567.
85. Guo NH, Krutzsch HC, Nègre E, Vogel T, Blake DA, Roberts DD. 1992. Heparin-and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. Proc Natl Acad Sci 89: 3040-3044.
86. Min/+ mouse model. Carcinogenesis 24: 199-207.
87. Halász K, Kassner A, Mörgelin M, Heinegård D. 2007. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 282: 31166-31173.
88. Hankenson KD, Bain SD, Kyriakides TR, Smith EA, Goldstein SA, Bornstein P. 2000. Increased marrow-derived osteoprogenitor cells and endosteal bone formation in mice lacking thrombospondin 2. J Bone Miner Res 15: 851-862.
89. Hankenson KD, James IE, Apone S, Stroup GB, Blake SM, Liang X, Lark MW, Bornstein P. 2005a. Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2-null mice. Matrix Biol 24: 362-370.
90. Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P. 2005b. Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol 25: 5599-5606.
91. Hankenson KD, Ausk BJ, Bain SD, Bornstein P, Gross TS, Srinivasan S. 2006. Mice lacking thrombospondin 2 show an atypical pattern of endocortical and periosteal bone formation in response to mechanical loading. Bone 38: 310-316.
92. Hankenson KD, Sweetwyne MT, Shitaye H, Posey KL. 2010. Thrombospondins and novel TSR-containing proteins, R-spondins, regulate bone formation and remodeling. Curr Osteoporos Rep 8: 68-76.
93. Hansen U, Platz N, Becker A, Bruckner P, Paulsson M, Zaucke F. 2011. A secreted variant of cartilage oligomeric matrix protein carrying a chondrodysplasia-causing mutation (p. H587R) disrupts collagen fibrillogenesis. Arthritis Rheum 63: 159-167.
94. Hauser N, Paulsson M, Kale AA, DiCesare PE. 1995. Tendon extracellular matrix contains pentameric thrombospondin-4 (TSP-4). FEBS Lett 368: 307-310.
95. Hawighorst T, Velasco P, Streit M, Hong YK, Kyriakides TR, Brown LF, Bornstein P, Detmar M. 2001. Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host anti-tumor defense mechanism. EMBOJ 20: 2631-2640.
96. Hecht JT, Nelson LD, Crowder E, Wang Y, Elder FF, Harrison WR, Francomano CA, Prange CK, Lennon GG, Deere M, et al. 1995. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nat Genet 10: 325-329.
97. Hecht JT, Deere M, Putnam E, Cole W, Vertel B, Chen H, Lawler J. 1998. Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Matrix Biol 17: 269-278.
98. Hecht JT, Hayes E, Snuggs M, Decker G, Montufar-Solis D, Doege K, Mwalle F, Poole R, Stevens J, Duke PJ. 2001. Calreticulin, PDI, Grp94 and BiP chaperone proteins are associated with retained COMP in pseudoachondroplasia chondrocytes. Matrix Biol 20: 251-262.
99. HessD, Keusch JJ, Oberstein SA, Hennekam RC, Hofsteenge J. 2008. Peters Plus syndrome is a newcongenital disorder of glycosylation and involves defective O-glycosylation of thrombospondin type 1 repeats. J Biol Chem 283: 7354-7360.
100. Hirose Y, Chiba K, Karasugi T, Nakajima M, Kawaguchi Y, Mikami Y, Furuichi T, Mio F, Miyake A, Miyamoto T, et al. 2008. A functional polymorphism in THBS2 that affects alternative splicing and MMP binding is associated with lumbar-disc herniation. Am J Hum Genet 82: 1122-1129.
101. Hiscott P, Sorokin L, Schlötzer-Schrehardt U, Blüthner K, Endress K, Mayer U. 1996. Expression of thrombospondin 1 by adult lens epithelium. Exp Eye Res 62: 709-712.
102. Hiscott P, Seitz B, Schlötzer-Schrehardt U, Naumann GO. 1997. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res 289: 307-310.
103. Hochegger K, Knight S, Hugo C, Mayer G, Lawler J, Mayadas TN, Rosenkranz AR. 2004. Role of thrombospondin-1 in the autologous phase of an accelerated model of antiglomerular basement membrane glomerulonephritis. Nephron Exp Nephrol 96: e31-e38.
104. Hoffman JR, Dixit VM, O'Shea KS. 1994. Expression of thrombospondin in the adult nervous system. J Comp Neurol 340: 126-139.
105. Hofsteenge J, Huwiler KG, Macek B, Hess D, Lawler J, Mosher DF, Peter-Katalinic J. 2001. C-mannosylation and O-fucosylation of the thrombospondin type 1 module. J Biol Chem 276: 6485-6498.
106. Hogg PJ, Owensby DA, Mosher DF, Misenheimer TM, Chesterman CN. 1993. Thrombospondin is a tightbinding competitive inhibitor of neutrophil elastase. J Biol Chem 268: 7139-7146.
107. Holden P, Meadows RS, Chapman KL, Grant ME, Kadler KE, Briggs MD. 2001. Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family. J Biol Chem 276: 6046-6055.
108. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D, Engel J, Tschopp J, Schneider P. 2000. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 237: 159-173.
109. Howell BG, Wang B, Freed I, Mamelak AJ, Watanabe H, Sauder DN. 2004. Microarray analysis of UVB-regulated genes in keratinocytes: downregulation of angiogenesis inhibitor thrombospondin-1. J Dermatol Sci 34: 185-194.
110. Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV. 2004. Peroxisome proliferator-activated receptor g ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2: 541-550.
111. Hughes EG, Elmariah SB, Balice-Gordon RJ. 2010. Astrocyte secreted proteins selectively increase hippocampal GABAergic axon length, branching, and synaptogenesis. Mol Cell Neurosci 43: 136-145.
112. Iruela-Arispe ML, Liska DJ, Sage EH, Bornstein P. 1993. Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev Dyn 197: 40-56.
113. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423-1431.
114. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. 2005. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMPdependent manner. Proc Natl Acad Sci 102: 13141-13146.
115. Isenberg JS, Wink DA, Roberts DD. 2006a. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 71: 785-793.
116. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. 2006b. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281: 26069-26080.
117. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. 2007a. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282: 15404-15415.
118. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. 2007b. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109: 1945-1952.
119. Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD. 2007c. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 27: 2582-2588.
120. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD. 2008a. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111: 613-623.
121. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, Tsokos M, Wink DA, Roberts DD. 2008b. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 173: 1100-1112.
122. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. 2009. Regulation of nitric oxide signalling by thrombospondin 1: Implications for anti-angiogenic therapies. Nat Rev Cancer 9: 182-194.
123. Jaffe EA, Ruggiero JT, Leung LK, Doyle MJ, McKeown-Longo PJ, Mosher DF. 1983. Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc Natl Acad Sci 80: 998-1002.
124. Jimenez B, Volpert OV, Crawford V, Febbraio M, Silverstein R, Bouck N. 2000. Signals leading to apoptosisdependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48.
125. Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N. 2001. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 20: 3443-3448.
126. KalasW, Yu JL, Milsom C, Rosenfeld J, Benezra R, Bornstein P, Rak J. 2005. Oncogenes and angiogenesis: Downregulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 65: 8878-8886.
127. Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas SA, Aamodt K, et al. 2009. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal pp53 and Tsp-1. Proc Natl Acad Sci 106: 12115-12120.
128. Ketis NV, Lawler J, Hoover RL, Karnovsky MJ. 1988. Effects of heat shock on the expression of thrombospondin by endothelial cells in culture. J Cell Biol 106: 893-904.
129. Kim HZ, Jung K, Kim HM, Cheng Y, Koh GY. 2009. A designed angiopoietin-2 variant, pentameric COMPAng2, strongly activates Tie2 receptor and stimulates angiogenesis. Biochim Biophys Acta 1793: 772-780.
130. Kipnes JR, Xu L, Han F, Rallapalli R, Jimenez S, Hall DJ, Tuan RS, Li Y. 2000. Molecular cloning and expression patterns of mouse cartilage oligomeric matrix protein gene. Osteoarthritis Cartilage 8: 236-239.
131. Koch W, Hoppmann P, de Waha A, Schömig A, Kastrati A. 2008. Polymorphisms in thrombospondin genes and myocardial infarction: A case-control study and a metaanalysis of available evidence. Hum Mol Genet 17: 1120-1126.
132. Kopp HG, HooperAT, Broekman MJ, Avecilla ST, Petit I, Luo M, Milde T, Ramos CA, Zhang F, Kopp T, et al. 2006. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 116: 3277-3291.
133. Kozma K, Keusch JJ, Hegemann B, Luther KB, KleinD, Hess D, Haltiwanger RS, Hofsteenge J. 2006. Identification and characterization of a β1,3-glucosyltransferase that synthesizes the Glc-β1,3-Fuc disaccharide on thrombospondin type 1 repeats. J Biol Chem 281: 36742-36751.
134. Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD. 1999. Identification of an a(3)b(1) integrin recognition sequence in thrombospondin-1. J Biol Chem 274: 24080-24086.
135. Kuznetsov G, Chen LB, Nigam SK. 1997. Multiple molecular chaperones complexwith misfolded large oligomeric glycoproteins in the endoplasmic reticulum. J Biol Chem 272: 3057-3063.
136. Kuznetsova SA, Issa P, Perruccio EM, Zeng B, Sipes JM, Ward Y, Seyfried NT, Fielder HL, Day AJ, Wight TN, et al. 2006. Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells. J Cell Sci 119: 4499-4509.
137. Kvansakul M, Adams JC, Hohenester E. 2004. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J 23: 1223-1233.
138. Kyriakides TR, Zhu YH, Yang Z, Bornstein P. 1998a. The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J Histochem Cytochem 46: 1007-1015.
139. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, DanielsonKG, Iozzo RV, LaMarca M, McKinney CE, et al. 1998b. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. JCell Biol 140: 419-430.
140. Kyriakides TR, Tam JW, Bornstein P. 1999a. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113: 782-787.
141. Kyriakides TR, Leach KJ, Hoffman AS, RatnerBD, Bornstein P. 1999b. Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci 96: 4449-4454.
142. Kyriakides TR, Rojnuckarin P, Reidy MA, Hankenson KD, Papayannopoulou T, Kaushansky K, Bornstein P. 2003. Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood 101: 3915-3923.
143. Laherty CD, O'Rourke K, Wolf FW, Katz R, Seldin MF, Dixit VM. 1992. Characterization of mouse thrombospondin 2 sequence and expression during cell growth and development. J Biol Chem 267: 3274-3281.
144. Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian UH, Bornstein P, Detmar M. 2002. Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice. Blood 99: 538-545.
145. Lawler J, Hynes RO. 1989. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood 74: 2022-2027.
146. Lawler JW, Slayter HS. 1981. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin. Thromb Res 22: 267-279.
147. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. 1985. The structure of human platelet thrombospondin. J Biol Chem 260: 3762-3772.
148. Lawler J, Weinstein R, Hynes RO. 1988. Cell attachment to thrombospondin: The role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol 107: 2351-2361.
149. Lawler J, Ferro P, Duquette M. 1992. Expression and mutagenesis of thrombospondin. Biochemistry 31: 1173-1180.
150. Lawler J, Duquette M, Whittaker CA, Adams JC, McHenry K, DeSimone DW. 1993. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol 120: 1059-1067.
151. Lawler J, McHenry K, Duquette M, Derick L. 1995. Characterization of human thrombospondin-4. J Biol Chem 270: 2809-2814.
152. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. 1998. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101: 982-992.
153. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO. 2001. Thrombospondin-1 gene expression affects survival and tumor spectrum of pp53-deficient mice. Am J Pathol 159: 1949-1956.
154. Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML. 2006. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 25: 5270-5283.
155. LiauwJ, Hoang S, Choi M, Eroglu C, Choi M, Sun GH, Percy M, Wildman-Tobriner B, Bliss T, Guzman RG, et al. 2008. Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. J Cereb Blood Flow Metab 28: 1722-1732.
156. Liu CJ, Kong W, Xu K, Luan Y, Ilalov K, Sehgal B, Yu S, Howell RD, Di Cesare PE. 2006a. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 281: 15800-15808.
157. Liu CJ, Kong W, Ilalov K, Yu S, Xu K, Prazak L, Fajardo M, Sehgal B, Di Cesare PE. 2006b. ADAMTS-7: A metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 20: 988-990.
158. Liu A, Garg P, Yang S, Gong P, Pallero MA, Annis DS, Liu Y, Passaniti A, Mann D, Mosher DF, et al. 2009. Epidermal growth factor-like repeats of thrombospondins activate phospholipase Cg and increase epithelial cell migration through indirect epidermal growth factor receptor activation. J Biol Chem 284: 6389-6402.
159. Luo Y, Koles K, Vorndam W, Haltiwanger RS, Panin VM. 2006. Protein O-fucosyltransferase 2 adds O-fucose to thrombospondin type 1 repeats. J Biol Chem 281: 9393-9399.
160. LymnJS, Patel MK, Clunn GF, Rao SJ, Gallagher KL, Hughes AD. 2002. Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level. J Cell Sci 115: 4353-4360.
161. Maclauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR. 2009. Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9, and soluble VEGF. J Histochem Cytochem 57: 301-313.
162. Majack RA, Cook SC, Bornstein P. 1985. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J Cell Biol 101: 1059-1070.
163. Majack RA, Cook SC, Bornstein P. 1986. Control of smooth muscle cell growth by components of the extracellular matrix: Autocrine role for thrombospondin. Proc Natl Acad Sci 83: 9050-9054.
164. Malek MH, Olfert IM. 2009. Global deletion of thrombospondin-1 increases cardiac and skeletal muscle capillarity and exercise capacity in mice. Exp Physiol 94: 749-760.
165. Mann HH, Ozbek S, Engel J, Paulsson M, Wagener R. 2004. Interactions between the cartilage oligomeric matrix protein and matrilins. Implications for matrix assembly and the pathogenesis of chondrodysplasias. J Biol Chem 279: 25294-25298.
166. Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, Urbinati C, Giavazzi R, Presta M, Ribatti D, Mosher DF, et al. 2008. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Bio 40: 700-709.
167. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, et al. 2007. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30: 303-309.
168. Marteau F, Gonzalez NS, Communi D, Goldman M, Boeynaems JM, Communi D. 2005. Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 106: 3860-3866.
169. Martin-Manso G, Galli S, Ridnour LA, Tsokos M, WinkDA, Roberts DD. 2008. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 68: 7090-7099.
170. McKenzie P, Chadalavada SC, Bohrer J, Adams JC. 2006. Phylogenomic analysis of vertebrate thrombospondins reveals fish-specific paralogues, ancestral gene relationships and a tetrapod innovation. BMC Evol Biol 6: 33.
171. McKeown-Longo PJ, Hanning R, Mosher DF. 1984. Binding and degradation of platelet thrombospondin by cultured fibroblasts. J Cell Biol 98: 22-28.
172. Meek RL, Cooney SK, Flynn SD, Chouinard RF, Poczatek MH, Murphy-Ullrich JE, Tuttle KR. 2003. Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Renal Physiol 285: F79-F86.
173. Meng H, Zhang X, Hankenson KD, Wang MM. 2009. Thrombospondin 2 potentiates notch3/jagged1 signaling. J Biol Chem 284: 7866-7874.
174. Meng H, Zhang X, Lee SJ, Strickland DK, Lawrence DA, Wang MM. 2010. LDL-receptor related protein (LRP1) regulates Thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem 285:23047-23055.
175. Merle B, Malaval L, Lawler J, Delmas P, Clezardin P. 1997. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem 67: 75-83.
176. Merritt TM, Bick R, Poindexter BJ, Alcorn JL, Hecht JT. 2007. Unique matrix structure in the rough endoplasmic reticulum cisternae of pseudoachondroplasia chondrocytes. Am J Pathol 170: 293-300.
177. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. 2001. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and-independent mechanisms. Cancer Res 61: 7830-7839.
178. Mikhailenko I, Kounnas MZ, Strickland DK. 1995. Low density lipoprotein receptor-related protein/α 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem 270: 9543-9549.
179. Mikhailenko I, KrylovD, Argraves KM, RobertsDD, Liau G, Strickland DK. 1997. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem 272: 6784-6791.
180. Möller JC, Klein MA, Haas S, Jones LL, Kreutzberg GW, Raivich G. 1996. Regulation of thrombospondin in the regenerating mouse facial motor nucleus. Glia 17: 121-132.
181. Mörgelin M, Heinegård D, Engel J, Paulsson M. 1992. Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. J Biol Chem 267: 6137-6141.
182. Motegi K, Harada K, Ohe G, Jones SJ, Ellis IR, Crouch DH, Schor SL, Schor AM. 2008. Differential involvement of TGF-β1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells. Exp Cell Res 314: 2323-2333.
183. Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF. 2007. Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol 27: 2163-2169.
184. -/-mice. Circ Res 103: 1181-1189.
185. Murphy-Ullrich JE, Mosher DF. 1985. Localization of thrombospondin in clots formed in situ. Blood 66: 1098-1104.
186. Murphy-Ullrich JE, Mosher DF. 1987a. Interactions of thrombospondin with endothelial cells: Receptormediated binding and degradation. J Cell Biol 105: 1603-1611.
187. Murphy-Ullrich JE, Mosher DF. 1987b. Interactions of thrombospondinwith cells in culture: Rapid degradation of both soluble and matrix thrombospondin. Semin Thromb Hemost 13: 343-351.
188. Murphy-Ullrich JE, Westrick LG, Esko JD, Mosher DF. 1988. Altered metabolism of thrombospondin by Chinese hamster ovary cells defective in glycosaminoglycan synthesis. J Biol Chem 263: 6400-6406.
189. Murphy-Ullrich JE, Gurusiddappa S, Frazier WA, Hook M. 1993. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J Biol Chem 268: 26784-26789.
190. Murphy-Ullrich JE, Pallero MA, Boerth N, Greenwood JA, Lincoln TM, Cornwell TL. 1996. Cyclic GMP-dependent protein kinase is required for thrombospondin and tenascin mediated focal adhesion disassembly. J Cell Sci 109: 2499-2508.
191. Mustonen E, Aro J, Puhakka J, Ilves M, Soini Y, Leskinen H, Ruskoaho H, Rysä J. 2008. Thrombospondin-4 expression is rapidly upregulated by cardiac overload. Biochem Biophys Res Commun 373: 186-191.
192. Narizhneva NV, Byers-Ward VJ, Quinn MJ, Zidar FJ, Plow EF, Topol EJ, Byzova TV. 2004. Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem 279: 21651-21657.
193. Narouz-Ott L, Maurer P, Nitsche DP, Smyth N, Paulsson M. 2000. Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains. J Biol Chem 275: 37110-37117.
194. Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Häuselmann HJ. 1997. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36: 1151-1160.
195. Newton G, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Lawler J. 1994. Characterization of human and mouse cartilage oligomeric matrix protein. Genomics 24: 435-439.
196. Nishimura H, Yamashita S, Zeng Z, Walz DA, Iwanaga S. 1992. Evidence for the existence of O-linked sugar chains consisting of glucose and xylose in bovine thrombospondin. J Biochem 111: 460-464.
197. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, et al. 2010. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci 107: 10649-10654.
198. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. 2008. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19: 563-571.
199. O'Leary JM, Hamilton JM, Deane CM, Valeyev NV, Sandell LJ, Downing AK. 2004. Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA. J Biol Chem 279: 53857-53866.
200. Orr AW, Pedraza CE, Pallero MA, Elzie CA, Goicoechea S, Strickland DK, Murphy-Ullrich JE. 2003. Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J Cell Biol 161: 1179-1189.
201. O'Shea KS, Dixit VM. 1988. Unique distribution of the extracellular matrix component thrombospondin in the developing mouse embryo. J Cell Biol 107: 2737-2748.
202. O'Shea KS, Liu LH, Dixit VM. 1991. Thrombospondin and a 140 kd fragment promote adhesion and neurite outgrowth from embryonic central and peripheral neurons and from PC12 cells. Neuron 7: 231-237.
203. Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE. 2008. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 22: 3968-3979.
204. Patel MK, Lymn JS, Clunn GF, Hughes AD. 1997. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2107-2114.
205. Phelan MW, Forman LW, Perrine SP, Faller DV. 1998. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 132: 519-529.
206. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ. 2004. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279: 21439-21448.
207. Pongsomboon S, Wongpanya R, Tang S, Chalorsrikul A, Tassanakajon A. 2008. Abundantly expressed transcripts in the lymphoid organ of the black tiger shrimp, Penaeus monodon, and their implication in immune function. Fish Shellfish Immunol 25: 485-493.
208. Posey KL, Hecht JT. 2008. The role of cartilage oligomeric matrix protein (COMP) in skeletal disease. Curr Drug Targets 9: 869-877.
209. Posey KL, Hankenson K, Veerisetty AC, Bornstein P, Lawler J, Hecht JT. 2008. Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol 172: 1664-1674.
210. Posey KL, Liu P, Wang HR, Veerisetty AC, Alcorn JL, Hecht JT. 2010. RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein. PLoS One 5: e10302.
211. Prabakaran D, Kim P, Kim KR, Arvan P. 1993. Polarized secretion of thrombospondin is opposite to thyroglobulin in thyroid epithelial cells. J Biol Chem 268: 9041-9048.
212. PrabakaranD, Kim PS, Dixit VM, Arvan P. 1996. Oligomeric assembly of thrombospondin in the endoplasmic reticulum of thyroid epithelial cells. Eur JCell Biol 70: 134-141.
213. Prabakaran D, Ahima RS, Harney JW, Berry MJ, Larsen PR, Arvan P. 1999. Polarized targeting of epithelial cell proteins in thyrocytes and MDCK cells. J Cell Sci 112: 1247-1256.
214. Preechaphol R, Leelatanawit R, Sittikankeaw K, Klinbunga S, Khamnamtong B, Puanglarp N, Menasveta P. 2007. Expressed sequence tag analysis for identification and characterization of sex-related genes in the giant tiger shrimp Penaeus monodon. J Biochem Mol Biol 40: 501-510.
215. Primo L, Ferrandi C, Roca C, Marchiò S, di Blasio L, Alessio M, Bussolino F. 2005. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 19: 1713-1715.
216. Prochownik EV, O'Rourke K, Dixit VM. 1989. Expression and analysis of COOH-terminal deletions of the human thrombospondin molecule. J Cell Biol 109: 843-852.
217. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, Lawler JW, Gutierrez LS. 2008. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75: 9-21.
218. Qabar AN, Lin Z, Wolf FW, O'Shea KS, Lawler J, Dixit VM. 1994. Thrombospondin 3 is a developmentally regulated heparin binding protein. J Biol Chem 269: 1262-1269.
219. Qabar A, Derick L, Lawler J, DixitV. 1995. Thrombospondin 3 is a pentameric molecule held together by interchain disulfide linkage involving two cysteine residues. J Biol Chem 270: 12725-12729.
220. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. 2007. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 282: 5704-5714.
221. Raugi GJ, Mumby SM, Abbott-Brown D, Bornstein P. 1982. Thrombospondin: synthesis and secretion by cells in culture. J Cell Biol 95: 351-354.
222. Raugi GJ, Mumby SM, Ready CA, Bornstein P. 1984. Location and partial characterization of the heparin-binding fragment of platelet thrombospondin. Thromb Res 36: 165-175.
223. Raugi GJ, Olerud JE, Gown AM. 1987. Thrombospondin in early human wound tissue. J Invest Dermatol 89: 551-554.
224. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR. 1990. Thrombospondin deposition in rat carotid artery injury. Am J Pathol 137: 179-185.
225. Recklies AD, Baillargeon L, White C. 1998. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 41: 997-1006.
226. Ren B, Yee KO, Lawler J, Khosravi-Far R. 2006. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765: 178-188.
227. Ren B, Song K, Parangi S, Jin T, Ye M, Humphreys R, Duquette M, Zhang X, Benhaga N, Lawler J, et al. 2009. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856-3865.
228. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. 1999. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem 274: 13586-13593.
229. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. 2005. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci 102: 13147-13152.
230. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J. 2001. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 47-54.
231. Rodrigues RG, Guo N, Zhou L, Sipes JM, Williams SB, Templeton NS, Gralnick HR, Roberts DD. 2001. Conformational regulation of the fibronectin binding and α 3β 1 integrin-mediated adhesive activities of thrombospondin-1. J Biol Chem 276: 27913-27922.
232. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. 2001. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci 98: 12485-12490.
233. Rosenberg K, Olsson H, Mörgelin M, Heinegård D. 1998. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 273: 20397-20403.
234. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL, Tulenko TN, Tuszynski GP. 1998. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res 74: 11-16.
235. Saito A, Hino S, Murakami T, Kanemoto S, Kondo S, Saitoh M, Nishimura R, Yoneda T, Furuichi T, Ikegawa S, et al. 2009. Regulation of endoplasmic reticulum stress response by a BBF2H7-mediated Sec23a pathway is essential for chondrogenesis. Nat Cell Biol 11: 1197-1204.
236. Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, Baker HV, Renne R. 2007. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog 3: e65.
237. San Antonio JD, Slover J, Lawler J, Karnovsky MJ, Lander AD. 1993. Specificity in the interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin. Biochemistry 32: 4746-4755.
238. Sato T, Sato M, Kiyohara K, Sogabe M, Shikanai T, Kikuchi N, Togayachi A, Ishida H, Ito H, Kameyama A, et al. 2006. Molecular cloning and characterization of a novel human β1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. Glycobiology 16: 1194-1206.
239. Schlötzer-Schrehardt U, Dietrich T, Saito K, Sorokin L, Sasaki T, Paulsson M, Kruse FE. 2007. Characterization of extracellular matrix components in the limbal epithelial stem cell compartment. Exp Eye Res 85: 845-860.
240. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, Evelo CT, Duisters R, van Leeuwen RE, et al. 2004. Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failure-prone cardiac hypertrophy. Circ Res 95: 515-522.
241. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. 1995. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310.
242. Scott-Burden T, Hahn AW, Resink TJ, Bühler FR. 1990. Modulation of extracellular matrix by angiotensin II: Stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. J Cardiovasc Pharmacol 16 (Suppl 4): S36-S41.
243. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, et al. 2005. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101-111.
244. Shitaye HS, Terkhorn SP, Combs JA, Hankenson KD. 2010. Thrombospondin-2 is an endogenous adipocyte inhibitor. Matrix Biol 29: 549-556.
245. Simantov R, Febbraio M, Silverstein RL. 2005. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24: 27-34.
246. Södersten F, Ekman S, Schmitz M, Paulsson M, Zaucke F. 2006. Thrombospondin-4 and cartilage oligomeric matrix protein form heterooligomers in equine tendon. Connect Tissue Res 47: 85-91.
247. Sottile J, Selegue J, Mosher DF. 1991. Synthesis of truncated amino-terminal trimers of thrombospondin. Biochemistry 30: 6556-6562.
248. Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, Plow EF. 2003. Thrombospondin-4 and its variants: Expression and differential effects on endothelial cells. Circulation 108: 1514-1519.
249. Stenina OI, Ustinov V, Krukovets I, Marinic T, Topol EJ, Plow EF. 2005. Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. FASEB J 19: 1893-1895.
250. Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendás AM, Llano E, Perris R, Di Cesare PE, Murphy G, Knäuper V. 2000. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 478: 52-56.
251. Streit M, Stephen AE, Hawighorst T, Matsuda K, Lange-Asschenfeldt B, Brown LF, Vacanti JP, Detmar M. 2002. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 62: 2004-2012.
252. Subramanian A, Wayburn B, Bunch T, Volk T. 2007. Thrombospondin-mediated adhesion is essential for the formation of the myotendinous junction in Drosophila. Development 134: 1269-1278.
253. Sun X, Skorstengaard K, Mosher DF. 1992. Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J Cell Biol 118: 693-701.
254. Sun YD, Zhao XF, Kang CJ, Wang JX. 2006. Molecular cloning and characterization of Fc-TSP from the Chinese shrimp Fennerpenaeus chinensis. Mol Immunol 43: 1202-1210.
255. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, Swerlick R, Bornstein P, Lawler J, Benjamin LE. 2009. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 296: H1344-H1351.
256. Svensson L, Aszódi A, Heinegård D, Hunziker EB, Reinholt FP, Fässler R, Oldberg A. 2002. Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol Cell Biol 22: 4366-4371.
257. Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MW, D'Hooge J, Van der Velden J, Weaver MS, Sage EH, Bornstein P, et al. 2009. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 120: 1585-1597.
258. Tada H, Isogai S. 1998. The fibronectin production is increased by thrombospondin via activation of TGF-β in cultured human mesangial cells. Nephron 79: 38-43.
259. Takagi J, Fujisawa T, Usui T, Aoyama T, Saito Y. 1993. A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin. J Biol Chem 268: 15544-15549.
260. Tan K, Duquette M, Liu JH, Zhang R, Joachimiak A, Wang JH, Lawler J. 2006. The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. Structure 14: 33-42.
261. Tan K, Duquette M, Liu JH, Shanmugasundaram K, Joachimiak A, Gallagher JT, Rigby AC, Wang JH, Lawler J. 2008. Heparin-induced cis-and trans-dimerization modes of the thrombospondin-1 N-terminal domain. J Biol Chem 283: 3932-3941.
262. Tan K, Duquette M, Joachimiak A, Lawler J. 2009. The crystal structure of the signature domain of cartilage oligomeric matrix protein: Implications for collagen, glycosaminoglycan and integrin binding. FASEB J 23: 2490-2501.
263. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. 2002. Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. J Cell Biol 159: 373-382.
264. Taylor DK, Meganck JA, Terkhorn S, Rajani R, Naik A, O'Keefe RJ, Goldstein SA, Hankenson KD. 2009. Thrombospondin-2 influences the proportion of cartilage and bone during fracture healing. J Bone Miner Res 24: 1043-1054.
265. Thakar CV, Zahedi K, Revelo MP, Wang Z, Burnham CE, Barone S, Bevans S, Lentsch AB, Rabb H, Soleimani M. 2005. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 115: 3451-3459.
266. Thur J, Rosenberg K, Nitsche DP, Pihlajamaa T, Ala-Kokko L, Heinegård D, Paulsson M, Maurer P. 2001. Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX. J Biol Chem 276: 6083-6092.
267. Tingaud-Sequeira A, Chauvigné F, Lozano J, Agulleiro MJ, Asensio E, Cerdà J. 2009. New insights into molecular pathways associated with flatfish ovarian development and atresia revealed by transcriptional analysis. BMC Genomics 10: 434.
268. Tooney PA, Sakai T, Sakai K, Aeschlimann D, Mosher DF. 1998. Restricted localization of thrombospondin-2 protein during mouse embryogenesis: A comparison to thrombospondin-1. Matrix Biol 17: 131-143.
269. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O'Donnell CJ, et al. 2001. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104: 2641-2644.
270. Tucker RP. 1993. The in situ localization of tenascin splice variants and thrombospondin 2 mRNA in the avian embryo. Development 117: 347-358.
271. Tucker RP. 2004. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969-974.
272. Tucker RP, Adams JC, Lawler J. 1995. Thrombospondin-4 is expressed by early osteogenic tissues in the chick embryo. Dev Dyn 203: 477-490.
273. Tucker RP, Hagios C, Chiquet-Ehrismann R, Lawler J. 1997. In situ localization of thrombospondin-1 and thrombospondin-3 transcripts in the avian embryo. Dev Dyn 208: 326-337.
274. Ueno A, Miwa Y, Miyoshi K, Horiguchi T, Inoue H, Ruspita I, Abe K, Yamashita K, Hayashi E, Noma T. 2006. Constitutive expression of thrombospondin 1 in MC3T3-E1 osteoblastic cells inhibits mineralization. J Cell Physiol 209: 322-332.
275. Urry LA, Whittaker CA, Duquette M, Lawler J, DeSimone DW. 1998. Thrombospondins in early Xenopus embryos: Dynamic patterns of expression suggest diverse roles in nervous system, notochord, and muscle development. Dev Dyn 211: 390-407.
276. van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K. 2010. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 29: 3185-3195.
277. VeliceasaD, Ivanovic M, Hoepfner FT, Thumbikat P, Volpert OV, Smith ND. 2007. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. FEBS J 274: 6365-6377.
278. Vischer P, Beeck H, Voss B. 1985. Synthesis, intracellular processing and secretion of thrombospondin in human endothelial cells. Eur J Biochem 153: 435-443.
279. Voland C, Serre CM, Delmas P, Clezardin P. 2000. Plateletosteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1. J Bone Miner Res 15: 361-368.
280. VolpertOV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. 2002a. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2: 473-483.
281. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. 2002b. Inducerstimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8: 349-357.
282. Vos HL, Devarayalu S, de Vries Y, Bornstein P. 1992. Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. J Biol Chem 267: 12192-12196.
283. Vranka J, Mokashi A, Keene DR, Tufa S, Corson G, Sussman M, HortonWA, Maddox K, Sakai L, Bächinger HP. 2001. Selective intracellular retention of extracellular matrix proteins and chaperones associated with pseudoachondroplasia. Matrix Biol 20: 439-450.
284. Wang TN, Qian X, Granick MS, SolomonMP, Rothman VL, Berger DH, Tuszynski GP. 1996. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63: 39-43.
285. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. 2003. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 228: 630-642.
286. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G. 2004a. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem 91: 766-776.
287. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. 2004b. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 279: 34311-34322.
288. Wang Y, Wang S, Sheibani N. 2006. Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. Microvasc Res 71: 143-151.
289. Wang J, Feng J, Shi M, Qian L, Chen L, Yu M, Xu R, Shen B, Guo N. 2008. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure. Mol Immunol 45: 106-116.
290. Watkins SC, Lynch GW, Kane LP, Slayter HS. 1990. Thrombospondin expression in traumatized skeletal muscle. Correlation of appearance with post-trauma regeneration. Cell Tissue Res 261: 73-84.
291. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. 1994. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54: 6504-6511.
292. Westphal JR. 2004. Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther 6: 451-457.
293. Wilson R, Diseberg AF, Gordon L, Zivkovic S, Tatarczuch L, Mackie EJ, Gorman JJ, Bateman JF. 2010. Comprehensive profiling of cartilage extracellular matrix formation and maturation using sequential extraction and label-free quantitative proteomics. Mol Cell Proteomics 9: 1296-1313.
294. Wu FR, Zhou LY, Nagahama Y, Wang DS. 2009. Duplication and distinct expression patterns of two thrombospondin-1 isoforms in teleost fishes. Gene Expr Patterns 9: 436-443.
295. Xu J, Xiao N, Xia J. 2010. Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat Neurosci 13: 22-24.
296. Yabkowitz R, Mansfield PJ, Ryan US, Suchard SJ. 1993. Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol 157: 24-32.
297. Yamano K, Qiu GF, Unuma T. 2004. Molecular cloning and ovarian expression profiles of thrombospondin, a major component of cortical rods in mature oocytes of penaeid shrimp, Marsupenaeus japonicus. Biol Reprod 70: 1670-1678.
298. Yang Z, Kyriakides TR, Bornstein P. 2000. Matricellular proteins as modulators of cell-matrix interactions: Adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell 11: 3353-3364.
299. Yang Z, Strickland DK, Bornstein P. 2001. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276: 8403-8408.
300. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. 2009. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 114: 85-96.
301. Young GD, Murphy-Ullrich JE. 2004. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-β complex. J Biol Chem 279: 47633-47642.
302. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. 2005. Thrombospondin plays a vital role in the immune privilege of the eye. Ocul Immunol Inflamm 15: 279-294.
303. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr, Ryeom S. 2010. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115: 4605-4613.
304. Zhang X, Lawler J. 2007. Thrombospondin-based antiangiogenic therapy. Microvasc Res 74: 90-99.
305. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J. 2009. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23: 3368-3376.
306. Zhou L, Isenberg JS, Cao Z, Roberts DD. 2006. Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1. Oncogene 25: 536-545.
307. Zhou J, Feng X, Ban B, Liu J, Wang Z, Xiao W. 2009. Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation. J Biol Chem 284: 19142-19152.
308. Ziaie Z, Friedman HM, Kefalides NA. 1986. Suppression of matrix protein synthesis by herpes simplex virus type 1 in human endothelial cells. Coll Relat Res 6: 333-349.